Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a report issued on Saturday. The firm set a "hold" rating on the biopharmaceutical company's stock.

ITCI has been the subject of a number of other reports. Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI remained flat at $131.87 during midday trading on Friday. Intra-Cellular Therapies has a one year low of $64.09 and a one year high of $131.98. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock's 50-day moving average is $129.91 and its 200-day moving average is $102.78.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities research analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Accredited Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth about $28,000. MassMutual Private Wealth & Trust FSB increased its stake in Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 133 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies in the third quarter valued at $97,000. Institutional investors own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.